5. Comparison of two non‐aminobisphosphonates: Roux 1995.
| Outcome | Tiludronate | Etidronate | RR (95% IC) | ||
| Events | N | Events | N | ||
| Number of participants with change in bone pain | 32 | 120 | 10 | 52 | 1.39 (0.74 to 2.61) |
| Number of participants with radiologically‐confirmed fractures | 1 | 155 | 2 | 79 | 0.25 (0.02 to 2.77) |
| Number of participants with severe side effects | 75 | 155 | 27 | 79 | 1.42 (1.00 to 2.00) |
| Number of participants who withdrew due to adverse events | 10 | 155 | 2 | 79 | 2.55 (0.57 to 11.35) |
| Number of participants who normalised alkaline phosphatase levels | 40 | 155 | 9 | 79 | 2.27 (1.16 to 4.43) |